Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors

Anna M van Eggermond1, Michael Schaapveld1,2, Cécile PM Janus3, Jan Paul de Boer4, Augustinus DG Kro1,5, Josée M Zijlstra6, Richard WM van der Maazen7, Leontien C Kremer8, Monique E van Leerdam9, Marieke WJ Louwman2, Otto Visser2, Marie L De Bruin10, Berthe MP Aleman11 and Flora E van Leeuwen*,1

1Department of Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands; 2Netherlands Comprehensive Cancer Organisation (IKNL), Hoog Catharijne, Godebaldkwartier 419, Utrecht 3511 DT, The Netherlands; 3Department of Radiation Oncology, Erasmus MC Cancer Institute, ’s-Gravendijkwal 230, Rotterdam 3015 CE, The Netherlands; 4Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands; 5Division of Radiation Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333 ZA, The Netherlands; 6Department of Hematology, VU University Medical Center, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands; 7Department of Radiation Oncology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen 6525 GA, The Netherlands; 8Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Meibergdreef 9, Amsterdam-Zuidoost 1015 AZ, The Netherlands; 9Department of Gastroenterology and Hepatology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 10Department of Pharmacy, Faculty of Health and Medical Science (CORS), University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark and 11Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands

Background: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens.

Methods: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates. Treatment effects were quantified by Cox regression analyses.

Results: After a median follow-up of 22.9 years, 55 patients developed CRC. The standardized incidence ratios (SIR) was 2.4-fold increased (95% confidence interval (95%CI) 1.8–3.2), leading to 5.7 excess cases per 10 000 patient-years. Risk was still increased 30 years after HL treatment (SIR: 2.8; 95%CI: 1.6–4.6). The highest (SIR: 6.5, 95%CI: 3.3–11.3) was seen for transverse colon cancer (15.0 (95%CI: 4.3–40.8) after inverted-Y irradiation). A prescribed cumulative procarbazine dose >4.2 g m⁻² was associated with a 3.3-fold higher CRC risk (95%CI: 1.8–6.1) compared to treatment without procarbazine. Patients receiving >4.2 g m⁻² procarbazine and infradiaphragmatic radiotherapy had a hazard ratio of 6.8 (95%CI: 3.0–15.6) compared with patients receiving neither treatment, which is significantly higher than an additive joint effect (Padditivity = 0.004).

Conclusions: Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy and a high cumulative procarbazine dose.
Due to the introduction of multi-agent chemotherapy and the continuing improvements in radiation techniques, Hodgkin lymphoma (HL) has become the prototype of a curable malignancy. Currently, the 10-year disease-specific survival is more than 85% for patients diagnose before 55 years of age (IKNL, 2012). As a result of this favourable prognosis, there is a growing population of HL survivors at risk of long-term complications caused by radiation therapy and chemotherapy. The risk of solid malignancies after HL treatment, especially risk of breast and lung cancer, has been studied extensively (Swerdlow et al., 2000; van Leeuwen et al., 2000; Dores et al., 2002; Ng et al., 2002; Travis et al., 2002; Travis et al., 2003; Hodgson et al., 2007; De Bruin et al., 2009; van den Belt-Dusebout et al., 2009; Swerdlow et al., 2011; Reulen et al., 2011; Swerdlov et al., 2012; Morton et al., 2013; Dores et al., 2014; Schaapveld et al., 2015). Although colorectal cancer (CRC) is the third most common solid malignancy in HL survivors (Hodgson et al., 2007; Schaapveld et al., 2015), so far few studies have specifically examined risk factors for CRC after HL treatment (Birdwell et al., 1997; Hodgson et al., 2007).

Colon and rectal cancers are often grouped together as they share genetic and epidemiological features (Schottenfeld Winawer, 1998; Network, 2012). Among Japanese atomic bomb survivors increased risk of colon, but not rectum cancer, emerged from 10 years after exposure (Nakatsuka et al., 1992; Nakachi et al., 2006; Preston et al., 2007). Excess rectum cancer risk was found after exposure to higher radiation doses (Land, 1986). Although in atomic bomb survivors, colon subsites showed equal sensitivity to radiation (Nakatsuka et al., 1992); studies of CRC risk among medically-irradiated subjects are complicated by the fact that the colon extends over a large part of the abdomen, and depending upon the radiation techniques, may receive markedly non-uniform doses. Surprisingly, CRC risk has not previously been assessed specifically for colorectal subsites.

Procarbazine has been shown to increase the risk of stomach (van den Belt-Dusebout et al., 2009; Morton et al., 2013) and lung cancer (Swerdlow et al., 2001; Travis et al., 2002) in HL patients. Although Morton and colleagues found statistically significant associations of stomach cancer risk with exposure to procarbazine or dacarbazine but not with other alkylating agents, in the study by Travis and colleagues lung cancer risk was associated both with exposure to mechlorethamine or procarbazine. It is unknown whether chemotherapy also affects CRC risk among HL survivors. However, alkylating agent exposure was associated with an 8.8-fold increased risk of CRC among childhood cancer survivors (9 out of 19 CRC diagnosed in childhood HL survivors) treated at St Jude Children’s Research Hospital (Nottage et al., 2012). Similarly, Henderson and colleagues previously reported that procarbazine independently increased risk, potentially in a dose–response manner, of gastrointestinal malignancies in childhood cancer survivors treated with abdominal irradiation (Henderson et al., 2012). Of note, out of 45 gastrointestinal malignancies, 20 were diagnosed among HL survivors and 24 were colorectal cancers. In this study, we therefore assessed the long-term subsite-specific risk of CRC after HL treatment, taking into account radiation fields and cumulative dose of alkylating agents, in a large multicenter Dutch cohort comprising 3121 5-year survivors of HL.

**PATIENTS AND METHODS**

Our cohort comprised of HL patients treated in seven Dutch University Hospitals or Cancer Centers and in the affiliated hospitals of the former population-based Eindhoven Cancer Registry. Patient selection and the data collection methods have been described in detail previously (van Leeuwen et al., 2000; De Bruin et al., 2009; Schaapveld et al., 2015). Briefly, patients were younger than 51 years at HL treatment (range: 3.6–50.9), first treated between 1965 and 1995 with radiation therapy and/or chemotherapy, and survived at least 5 years. The detailed treatment data (dates of start of treatment, radiation fields, chemotherapy regimens and number of cycles) were collected from the medical records, both for initial and relapse treatment. Up to 2004 data on second malignancy diagnoses were obtained from the medical records and by contacting general practitioners and attending physicians in other hospitals (94% complete follow-up) (De Bruin et al., 2009). Additionally, CRCs diagnoses between 2004 and January 2011 were ascertained through linkage with the nationwide PALGA network and registry of histo- and cytopathology (Casparie et al., 2007) and the Netherlands Cancer Registry (NCR). PALGA reached nation-wide coverage in January 1990 and the NCR in January 1989. Completeness of case ascertainment by the NCR is >98% (Schouten et al., 1994).

Colorectal cancers were classified according to the International Classification of Diseases for Oncology (ICD-O-3) (WHO, 2000). Colorectal cancers were categorised into ascending colon (including coecum and hepatic flexure), transverse colon (including splenic flexure), descending colon (including sigmoid colon), and rectum (including rectosigmoid junction). Each CRC was classified as ‘in field’, ‘out of field’ or ‘unknown’ based on review of the radiation fields by a radiation oncologist (BMPA). Vital status was obtained up to January 2011 through linkage with the Dutch Central Bureau of Genealogy; 2.7% of the patients had either emigrated or were otherwise lost-to-follow-up.

**Treatment.** Over time a wide variety of treatment regimens was used in the cohort. Although primary treatment was usually given in accordance with treatment protocols of the European Organisational for Research and Treatment of Cancer (Favier et al., 2009) for recurrences was generally not standardised. Patients usually received 40 Gy in 20 fractions when treated with radiation therapy only and 30–36 Gy in 15–20 fractions when they also received chemotherapy. Mantle field irradiation (mediastinal, axillary and neck nodes) was the most commonly applied radiation field from the early 1970s to the late 1980s. Infradiaphragmatic radiation, commonly including the para-aortic nodes and spleen (para-aortal field), but frequently also the iliac and inguinal nodes (inverted Y field), was given until the late 1980s as part of (sub)total nodal irradiation (Supplementary Figure 1). Since the late 1980s, a growing number of patients received more limited radiation fields. Information on radiation doses and fractionation schedules for individual patients was not routinely collected for all participating hospitals. From the late 1960s to the 1980s, chemotherapy consisted mainly of MOPP (mechlorethamine, vincristine, procarbazine, prednisone). In the 1980s, anthracycline-containing regimens such as MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine) and ABVD (doxorubicin, bleomycin, vinblastine, darcabazine) were introduced.

**Statistical analysis.** Colorectal cancer incidence in the cohort was compared with age-, sex-, subsite and calendar period-specific CRC incidence rates in the Dutch population, accounting for person-years of observation. The cancer incidence data from the Eindhoven Cancer Registry up to 1988 and from the Netherlands Cancer Registry from 1989 onwards were used as reference (IKNL, 2012).

Time at risk began 5 years after the start of HL treatment and ended at the date of CRC diagnosis, date of death or date of most recent medical information, whichever came first. HL was the first primary malignancy in all patients. Patients who developed a subsequent malignancy within 5-years after HL were excluded. All CRC diagnosed ≥5 years after start of HL treatment were retained in the analyses. Standardized incidence ratios (SIRs) were calculated as the ratios of the observed and expected numbers of
CRC in the cohort, and absolute excess risks (AERs) as the observed numbers of CRC in our cohort minus the expected numbers, divided by number of person-years at risk, multiplied by 10,000. Standardized incidence ratios were calculated for any CRC and for colon cancer subsites and rectal cancer separately; analyses were performed by sex, age at first HL treatment, follow-up interval, and type of treatment. Prescribed cumulative procarbazine doses were estimated using standard procarbazine doses per cycle in each chemotherapy regimen as a measure for alkylating chemotherapy; that is, three cycles of MOPP or six cycles of MOPP-ABV are equivalent to a prescribed cumulative procarbazine dose of 4.2 g m\(^{-2}\) of body surface area. For 172 patients (7.9% of chemotherapy-treated patients), the prescribed procarbazine dose was unknown. A multivariate single mean imputation approach was applied to account for missing procarbazine doses, under the missing at random assumption, using a multinomial logistic regression model. Variables used for imputation were sex, age, year and hospital at HL treatment, type of chemotherapy and number of cycles, and CRC occurrence (yes/no). Confidence intervals for SIRs and tests for homogeneity and trend of SIRs were calculated using standard methods (Breslow Day, 1987).

The cumulative incidence of CRC was estimated in the presence of death as a competing risk. Multivariable Cox regression analyses were performed to quantify the effects of HL treatment on CRC risk with time since start of HL treatment as time-scale. The proportional hazard assumption was assessed using residual-based methods. Variables considered in this analysis were sex, age and HL treatment. Interaction between a procarbazine dose \(\propto\) and infradiaphragmatic radiation therapy, the CRC was located within the radiation field in 46% and outside in 42%; for 12% this was unknown (Supplementary Table 1). The median time to CRC diagnosis was 22.9 years (IQR: 16.7–30.7) and median age at CRC diagnosis was 50.4 years (IQR 45.0–62.2; Table 1). The youngest CRC patient was 35 years at diagnosis. Most CRCS were stage 2 (38%) or higher (stage 3 (24%) and stage 4 (15%); Supplementary Table 1). At the end of follow-up, 43 CRC patients had died, of whom 17 (40%) due to CRC. The 5-year overall survival after CRC diagnosis was 31%.

### RESULTS

**Patient characteristics.** Median age at start of HL treatment was 27.3 years (interquartile range (IQR) 21.0–35.5; Table 1). Almost 50% had received infradiaphragmatic radiation therapy; 28% received chemotherapy and infradiaphragmatic radiation therapy combined. Chemotherapy mostly comprised of MOPP or MOPP-like chemotherapy; 35.8% of the patients treated with chemotherapy received > 4.2 g m\(^{-2}\) procarbazine-containing chemotherapy. Median follow-up was 22.9 years (IQR 16.7–30.7) and 23.4% of patients were followed 30 years.

Fifty-five HL survivors developed CRC; 34 patients had colon cancer and 21 rectal cancer. Among the 52 CRC patients treated with radiation therapy, the CRC was located within the radiation field in 46% and outside in 42%; for 12% this was unknown (Supplementary Table 1). The median time to CRC diagnosis was 22.9 years (IQR: 16.7–30.7) and median age at CRC diagnosis was 56.4 years (IQR: 50.6–62.2; Table 1). The youngest CRC patient was 35 years at diagnosis. Most CRCS were stage 2 (38%) or higher (stage 3 (24%) and stage 4 (15%); Supplementary Table 1). At the end of follow-up, 43 CRC patients had died, of whom 17 (40%) due to CRC. The 5-year overall survival after CRC diagnosis was 31%.

### Table 1. General characteristics of all Hodgkin lymphoma patients and colorectal cancer (CRC) patients

| Characteristic | All patients | Sex | | Age at first HL treatment (years) | | | | Stage HL | | | | Treatment period | | | | Follow-up (years) | | | | Treatment for HL | | | | CT treatment according to cumulative procarbazine dose | | | | Abbreviations: ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; CRC = colorectal cancer, CT = chemotherapy, EBVP = epirubicin, bleomycin, vinblastine, prednisone; HL = Hodgkin lymphoma; MOPP = mechlorethamine, vinblastine, procarbazine, prednisone; MOPP-ABV = mechlorethamine, vinblastine, procarbazine, prednisone – doxorubicin, bleomycin; EBVP = epirubicin, bleomycin, vinblastine, dacarbazine; PAO = para-aortic; IQR = inter quartile range; RT = radiation therapy. *In all, 218 patients (7.0%) were younger than 15 years at HL diagnosis. **Included primary and relapse therapy. RT includes all radiation fields. ***No RT or supradiaphragmatic RT only. ****Inverted Y field consists of para-aortic and iliac nodes. *****Includes iliac and inguinal fields. MOPP-like regimens include at least procarbazine, e.g. CVPP-LO, COPP, CHOPP, MMPP, LOPP. ******Includes single agents, other CT regimens, and CT agent unknown. *******Mutually exclusive categories.

| Characteristic | All patients | Sex | | Age at first HL treatment (years) | | | | Stage HL | | | | Treatment period | | | | Follow-up (years) | | | | Treatment for HL | | | | CT treatment according to cumulative procarbazine dose | | | | Abbreviations: ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; CRC = colorectal cancer, CT = chemotherapy, EBVP = epirubicin, bleomycin, vinblastine, prednisone; HL = Hodgkin lymphoma; MOPP = mechlorethamine, vinblastine, procarbazine, prednisone; MOPP-ABV = mechlorethamine, vinblastine, procarbazine, prednisone – doxorubicin, bleomycin; EBVP = epirubicin, bleomycin, vinblastine, dacarbazine; PAO = para-aortic; IQR = inter quartile range; RT = radiation therapy. *In all, 218 patients (7.0%) were younger than 15 years at HL diagnosis. **Included primary and relapse therapy. RT includes all radiation fields. ***No RT or supradiaphragmatic RT only. ****Inverted Y field consists of para-aortic and iliac nodes. *****Includes iliac and inguinal fields. MOPP-like regimens include at least procarbazine, e.g. CVPP-LO, COPP, CHOPP, MMPP, LOPP. ******Includes single agents, other CT regimens, and CT agent unknown. *******Mutually exclusive categories.

| Characteristic | All patients | Sex | | Age at first HL treatment (years) | | | | Stage HL | | | | Treatment period | | | | Follow-up (years) | | | | Treatment for HL | | | | CT treatment according to cumulative procarbazine dose | | | | Abbreviations: ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; CRC = colorectal cancer, CT = chemotherapy, EBVP = epirubicin, bleomycin, vinblastine, prednisone; HL = Hodgkin lymphoma; MOPP = mechlorethamine, vinblastine, procarbazine, prednisone; MOPP-ABV = mechlorethamine, vinblastine, procarbazine, prednisone – doxorubicin, bleomycin; EBVP = epirubicin, bleomycin, vinblastine, dacarbazine; PAO = para-aortic; IQR = inter quartile range; RT = radiation therapy. *In all, 218 patients (7.0%) were younger than 15 years at HL diagnosis. **Included primary and relapse therapy. RT includes all radiation fields. ***No RT or supradiaphragmatic RT only. ****Inverted Y field consists of para-aortic and iliac nodes. *****Includes iliac and inguinal fields. MOPP-like regimens include at least procarbazine, e.g. CVPP-LO, COPP, CHOPP, MMPP, LOPP. ******Includes single agents, other CT regimens, and CT agent unknown. *******Mutually exclusive categories.
Colorectal cancer risk by age at first and time since HL treatment.

The SIR of CRC was highest for patients treated <25 years of age (SIR: 2.2; 95%CI: 1.1–3.8) and 25–34 years, the risk of descending colon cancer was not (SIR: 1.2–6.4) 0.6 (0.2–1.3) 1.6 (0.7–3.0);

Sex

Men 34 3.2 (2.2–4.4) 7.4 (4.1–11.8) 0.7 (0.4–1.2) 2.0 (1.3–3.0)
Women 21 1.8 (1.1–2.7) 3.6 (0.5–7.9) 0.6 (0.3–1.1) 2.1 (1.2–3.5)
P-heterogeneity 0.04 0.13

Age at first HL treatment (years)

<25 17 4.9 (2.8–7.8) 5.2 (2.5–9.2) 0.2 (0.1–0.7) 1.1 (0.5–2.1)
25–34 16 2.3 (1.3–4.7) 4.9 (1.2–10.3) 0.2 (0.1–0.7) 2.5 (1.3–4.3)
35–50 22 1.8 (1.1–2.8) 7.8 (1.3–16.8) 1.9 (1.0–3.1) 3.3 (1.9–5.4)
P-trend 0.004 0.62

Treatment for HL

| Treatment category | Cases | SIR (95%CI) | AER (95%CI) | 20-year cumulative incidence (%) | 30-year cumulative incidence (%) |
|--------------------|-------|-------------|-------------|-----------------------------------|-----------------------------------|
| CT only            | 3     | 1.1 (0.2–3.3) | 0.6 (3.3–10.1) | 0.3 (0.0–1.7) | 0.8 (0.2–2.7) |
| Supradiaphragmatic RT, no CT | 3     | 0.9 (0.2–2.6) | 0.0 (3.6–7.2) | 0.3 (0.0–1.6) | 0.9 (0.2–3.3) |
| Supradiaphragmatic RT + CT | 13    | 2.0 (1.0–3.3) | 3.6 (2.8–8.9) | 0.3 (0.1–0.9) | 1.7 (0.8–3.4) |
| Infra-2 supradiaphragmatic RT, no CT | 9     | 1.8 (0.8–3.3) | 3.3 (–0.9–1.1) | 0.8 (0.3–1.8) | 2.0 (0.8–4.2) |
| Infra-2 supradiaphragmatic RT + CT | 27    | 5.7 (3.7–8.2) | 15.9 (9.3–24.7) | 1.2 (0.6–2.1) | 3.4 (2.0–5.2) |
| P-heterogeneity | 0.001 | 0.001 |

Infradiaphragmatic irradiation

| No infradiaphragmatic RT | 19 | 1.5 (0.9–2.3) | 2.0 (0.4–5.4) | 0.3 (0.1–0.7) | 1.4 (0.7–2.4) |
| PAO | 6 | 2.2 (0.8–4.8) | 4.9 (0.8–15.6) | 0.7 (0.1–2.3) | 2.2 (0.9–4.8) |
| PAO + spleen | 8 | 2.2 (1.0–4.4) | 4.0 (0.1–11.9) | 0.7 (0.2–1.7) | 1.3 (0.5–2.7) |
| Inverted Y ± spleen | 18 | 6.1 (3.6–9.6) | 21.1 (10.8–35.8) | 1.6 (0.7–3.3) | 4.2 (2.2–7.1) |
| Infradiaphragmatic other | 4 | 6.3 (1.7–16.2) | 18.1 (2.5–51.6) | 1.0 (0.1–4.9) | 4.4 (1.1–11.6) |
| P-heterogeneity | <0.001 | 0.02 |

CT treatment (according to cumulative procarbazine dose)

| No CT | 12 | 1.4 (0.7–2.5) | 1.8 (–1.6–4.4) | 0.6 (0.2–1.3) | 1.6 (0.7–3.0) |
| Non-alkylating CT only | 3 | 1.6 (0.3–4.8) | 3.6 (–3.8–21.6) | – | 2.3 (0.4–7.6) |
| Alkylating CT, no procarbazine | 1 | 0.8 (0.0–4.5) | – (0.3–13.8) | – | 3.1 (0.2–13.4) |
| Alkylating CT, <4.2 g m<sup>−2</sup> procarbazine | 5 | 1.8 (0.6–4.1) | 2.5 (–1.4–10.1) | 0.8 (0.3–1.8) | 2.0 (0.5–5.7) |
| Alkylating CT, 4.2–8.4 g m<sup>−2</sup> procarbazine | 17 | 3.7 (2.6–5.9) | 9.4 (2.2–17.9) | 0.9 (0.4–2.0) | 1.8 (0.9–3.2) |
| Alkylating CT, >8.4 g m<sup>−2</sup> procarbazine | 14 | 5.2 (2.9–8.8) | 16.2 (7.1–29.9) | 0.5 (0.1–1.8) | 3.4 (1.7–5.9) |
| CT, type unknown | 3 | 3.5 (0.7–10.7) | 7.0 (0.8–25.9) | 0.6 (0.1–3.1) | 1.6 (0.3–5.1) |
| P-heterogeneity | 0.01 | 0.05 |

Abbreviations: 95% CI = 95% confidence interval; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; AER = absolute excess risk per 10 000 person-years; CRC = colorectal cancer; CT = chemotherapy; EBVP = etoposide, bleomycin, vinblastine, prednisone; PAO = para-aortic; HL = Hodgkin lymphoma; MOPP = mechlorethamine, vincristine, procarbazine, prednisone; MOPP-ABVD = mechlorethamine, vincristine, procarbazine, prednisone + doxorubicin, bleomycin, vinblastine, dacarbazine; n.a. = not applicable; NOS = not otherwise specified; SIR = Standardized Incidence Ratio; RT = radiation therapy.

*p-value for trend across categories.

Colorectal cancer risk by age at first and time since HL treatment.

The SIR of CRC was highest for patients treated <25 years of age (SIR: 2.9; 95%CI: 2.5–3.3) and 25–34 years, the risk of descending colon cancer was not (SIR: 1.2–6.4) 0.6 (0.2–1.3) 1.6 (0.7–3.0); the AER was 3.6 at 10–19 years and 24.6 per 10 000 patients-years at ≥30 years of follow-up, respectively (data not shown).
Colorectal cancer after Hodgkin lymphoma

Risk factors for CRC: multivariable regression analysis. In multivariable Cox analyses (Table 4), infradiaphragmatic radiation therapy was associated with increased CRC risk (age- and sex-adjusted hazard ratio (HR) 2.8, 95%CI: 1.6–4.9). Patients treated with a procarbazine dose >4.2 g m⁻² also had an increased CRC-risk (HR: 3.3, 95%CI: 1.8–6.2) compared to patients receiving ≤4.2 g m⁻² of procarbazine. A very high CRC risk was seen for patients who had received both a procarbazine dose >4.2 g m⁻² and infradiaphragmatic radiation therapy (HR: 6.8, 95%CI: 3.0–15.6, compared with patients receiving none of these treatments). The combined effect of prescribed procarbazine dose and infradiaphragmatic radiation therapy showed departure from additivity (P<0.0043), pointing to a synergistic effect of procarbazine and infradiaphragmatic radiation therapy. The data did not support a supermultiplicative joint effect (P=0.153). This combined effect of a prescribed procarbazine dose >4.2 g m⁻² and infradiaphragmatic radiation therapy was stronger for transverse colon and rectal cancer, which were more often located in the radiation fields (HR: 10.1, 95%CI: 3.3–30.7).

Table 3. Risks of colorectal cancer after HL treatment; SIRs by sex, age, follow-up interval and treatment

| Tumour site | All colon sites (n = 34) | Transverse colon* (n = 12) | Colon other a (n = 22) | Rectum (n = 21) |
|-------------|-------------------------|---------------------------|-----------------------|----------------|
| Risk factor | O SIR 95% CI | O SIR 95% CI | O SIR 95% CI | O SIR 95% CI |
| Treatment for HL a | | | | |
| **CT only** | | | | |
| CT only | 1 0.6 0.3–1.6 | 0 — — | 1 0.7 0.3–2.9 | 1 2.0 0.2–7.7 |
| Supradiaphragmatic RT, no CT | 1 2.0 0.7–5.7 | 1 1.9 0.6–5.4 | 1 0.5 0.1–2.3 | 1 0.8 0.1–6.7 |
| Supradiaphragmatic RT + CT | 8 4.0 2.0–8.6 | 7 1.8 0.4–6.8 | 1 0.3 0.0–6.9 | 1 0.7 0.0–5.3 |
| Infra- = supradiaphragmatic RT, no CT | 7 4.0 1.6–14.5 | 1 0.5 0.0–2.2 | 1 0.5 0.0–2.2 | 1 0.6 0.0–3.6 |
| Infra- = supradiaphragmatic RT + CT | 16 5.5 3.1–9.9 | 8 4.0 1.6–9.4 | 8 3.0 1.3–6.6 | 11 5.9 2.9–10.5 |
| Treatment according to cumulative procarbazine dose a | | | | |
| No CT | 9 1.4 0.7–2.9 | 1 0.7 0.2–2.8 | 1 0.7 0.2–2.8 | 1 0.8 0.2–2.8 |
| Non-allalkylating CT only | 2 0.8 0.4–1.6 | 1 0.6 0.2–1.9 | 2 0.7 0.2–1.9 | 1 0.6 0.0–1.6 |
| Allalkylating CT, no procarbazine | 0 — — | 0 — — | 0 — — | 1 0.8 0.0–5.6 |
| Allalkylating CT, <4.2 g m⁻² procarbazine | 3 4.0 1.6–8.6 | 1 0.8 0.2–2.8 | 2 0.4 0.1–2.8 | 1 0.4 0.0–2.4 |
| Allalkylating CT, 4.2–8.4 g m⁻² procarbazine | 7 2.5 0.9–7.7 | 5 3.0 0.9–10.3 | 5 2.0 0.5–4.7 | 10 5.6 2.7–10.3 |
| Allalkylating CT, >8.4 g m⁻² procarbazine | 10 6.1 2.9–13.5 | 5 2.5 1.0–7.2 | 5 2.0 0.5–2.9 | 10 5.6 2.7–10.3 |
| CT, type unknown | 3 1.4 0.5–3.9 | 2 0.8 0.2–2.8 | 1 0.5 0.0–1.8 | 3 0.7 0.0–3.9 |
| Allalkylating CT, >4.2 g m⁻² procarbazine | 17 3.8 1.8–7.9 | 7 4.2 1.6–7.7 | 6 3.0 1.3–6.6 | 14 5.0 2.2–10.3 |

| Abbreviations: 95% CI = 95% confidence interval; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; AER = absolute excess risk per 10 000 person-years; Colon other = ascending colon, descending colon, colon not otherwise specified; CT = chemotherapy; EBVP = epirubicine, bleomycin, vinblastine, prednisone; MOPP = mechlorethamine, vincristine, procarbazine, prednisone; MOPP-ABVD = mechlorethamine, vincristine, procarbazine, prednisone—doxorubicin, bleomycin, vinblastine, dacarbazine; O = Observed number; PAO = para-aortic; RT = radiation therapy; SIR = Standardized Incidence Ratio.
| aIncludes transverse colon and splenic flexures.
| bIncludes ascending colon, cocum, hepatic flexura and descending colon.
| cIncludes primary and relapse therapy. RT includes all radiotherapy fields.
| dNo RT and supradiaphragmatic RT.
| eInverted Y field consists of para-aortic and iliac nodes.
| fMutually exclusive categories.

Transverse colon cancer had a strongly increased risk of developing CRC compared with the general population (SIR: 4.3, 95%CI: 2.9–6.1).
Table 4. Treatment-related risk factors for the occurrence of colorectal cancer during follow-up: multivariable Cox regression analysis

| Risk factor | Cohort | CRC | Transverse colon and rectum |
|-------------|--------|-----|-----------------------------|
|              | Total Cases HR 95% CI | Cases HR 95% CI |
| Treatment   |        |     |                             |
| Model I     |        |     |                             |
| Procarbazine |        |     |                             |
| No CT or CT without procarbazine | 1256 | 16 | 1.00 | Reference | 8 | 1.00 | Reference |
| CT, ≤4.2 g m⁻² procarbazine | 577 | 5 | 1.4 | 0.5–3.7 | 3 | 1.5 | 0.4–5.6 |
| CT, >4.2 g m⁻² procarbazine | 1117 | 31 | 3.3 | 1.8–6.1 | 21 | 4.8 | 2.1–10.9 |
| P-trend b |        |     |                             |
| Radiotherapy |        |     |                             |
| No infradiaphragmatic RT | 1643 | 19 | 1.00 | Reference | 10 | 1.00 | Reference |
| Infradiaphragmatic RT | 1478 | 36 | 2.8 | 1.6–4.9 | 23 | 3.5 | 1.7–7.5 |
| P-trend b |        |     |                             |
| Model I² d |        |     |                             |
| Procarbazine and radiotherapy |        |     |                             |
| No infradiaphragmatic RT, ≤4.2 g m⁻² procarbazine | 911 | 8 | 1.00 | Reference | 4 | 1.00 | Reference |
| No infradiaphragmatic RT, >4.2 g m⁻² procarbazine | 632 | 10 | 1.8 | 0.7–4.5 | 9 | 2.1 | 0.6–7.5 |
| Infradiaphragmatic RT, ≤4.2 g m⁻² procarbazine | 922 | 13 | 1.7 | 0.7–4.0 | 7 | 1.7 | 0.5–5.8 |
| Infradiaphragmatic RT, >4.2 g m⁻² procarbazine | 485 | 21 | 6.8 | 3.0–15.6 | 15 | 10.1 | 3.3–30.7 |
| P-heterogeneity b |        |     |                             |

Abbreviations: 95% CI = 95% confidence interval; CRC = colorectal cancer; CT = chemotherapy; HR = hazard ratio; RT = radiation therapy.

a Adjusted for age at HL diagnosis (continuously) and sex using time since diagnosis as time-scale. HRs for missing procarbazine dose not shown.

b P-values based on Likelihood ratio tests.
c Joint effect of procarbazine and radiotherapy for CRC: P-additivity = 0.043; P-multiplicativity = 0.153.
d Joint effect of procarbazine and radiotherapy for transverse colon & rectum: P-additivity = 0.004; P-multiplicativity = 0.199.

Cumulative incidence of CRC. The cumulative incidence of any CRC was 0.6% (95%CI: 0.4–1.0) at 20 years and 2.1% (95%CI: 1.4–2.8) at 30 years of follow-up (Table 2). Although, compared to younger patients, patients aged 35–50 years at HL treatment had a higher cumulative incidence of CRC throughout follow-up (30-year cumulative incidence 2.7%, 95%CI: 1.6–4.3%), their cumulative incidence did not differ much from the population expected CRC incidence (expected 30-year cumulative incidence of 2.7%). In contrast, the cumulative CRC incidence among patients <25 years at HL treatment was much higher than the population-expected CRC incidence throughout follow-up; the 30-year observed cumulative incidence was 1.0% (95%CI: 0.5–1.9%) compared to an expected cumulative incidence of 0.2% (Supplementary Figure 2). The 30-year cumulative incidence was 1.2% (95%CI: 0.8–1.9) for colon cancer and 0.8% (95%CI: 0.5–1.0) for rectal cancer. At the age of 55 years, currently the starting age for colorectal cancer screening in the Dutch population, the cumulative incidence of CRC was 2.4% (95%CI: 1.3–4.1%) for patients treated for HL <25 years of age, compared to an expected cumulative incidence of 0.6% assuming similar CRC rates as in the general population (Figure 1A). Hodgkin survivors treated for HL <25 years of age reached a cumulative incidence of 0.6% at 46.5 years of age. The cumulative incidence of CRC was 0.9% (95%CI: 0.4–1.8%) for patients treated for HL at age 25–34 years. For patients treated for HL before age 35 with both infradiaphragmatic radiation therapy and chemotherapy with a procarbazine dose >4.2 g m⁻², the cumulative incidence of CRC was 4.2% (95%CI: 2.3–7.1%) at the age of 55 years, compared to a general population expected cumulative incidence at age 55 years of 0.6% (Figure 1B). These HL patients already reached a cumulative incidence of 0.6% at an attained age of 38 years.

Discussion

To the best of our knowledge, this is the first study that assessed long-term subsite-specific CRC-risk after HL treatment in a large multicenter cohort of HL survivors. In our study, HL survivors had a 2.4-fold increased risk to develop CRC compared to the general population; risk was highest for cancer of the transverse colon. The increased CRC risk emerged late and the risk was still increased ≥30 years after first treatment. An inverted-Y field with/without spleen irradiation was associated with a 15.9-fold increased risk of transverse colon cancer and a 6.3-fold increased risk of rectal cancer. Our most important and novel finding is that CRC risk was especially increased in patients who had received both high-dose procarbazine and infradiaphragmatic radiation therapy (HR: 6.8, 95%CI: 3.0–15.6). This association was stronger for colorectal subsites, which were more likely exposed to higher radiation doses such as the transverse colon and rectum.

In the general population, colon cancer is most often located in the ascending and descending colon (Lemmens et al, 2010). While 12% of all colon cancers in the general population are located in the transverse colon (IKNL, 2012), in our population, 35.3% (12 out of 34) of CRCs were located in the transverse colon. Likely, this is due to the fact that the transverse colon receives a high radiation dose in standard infradiaphragmatic fields. In the atomic bomb survivors, who received whole body irradiation, the colon cancers subsite distribution did not differ by radiation dose, indicating that the different subsites of the colon seem equally sensitive to radiation (Nakatsuka et al, 1992). In a study by Henderson and colleagues (Henderson et al, 2012), evaluating gastrointestinal cancer risk among childhood cancer survivors, 82% of the gastrointestinal cancers were in or near the radiation fields. In line with our results, Nottage and colleagues also reported that among childhood cancer survivors second CRCs were more likely to develop in the irradiated segments of the colon (Nottage et al, 2012).

Exposure to alkylating agents, such as procarbazine, has been shown to increase the risk of several solid tumours in humans (Swerdlov et al, 2001; Travis et al, 2002; van den Belt-Dusebout et al, 2009; Morton et al, 2013; Dores et al, 2014). Our group previously reported increasing stomach cancer risk with higher doses of procarbazine in HL survivors, which was confirmed in a larger international study (van den Belt-Dusebout et al, 2009;
In accordance with other studies of second solid malignancy risk among HL patients, in our study, CRC relative risk was higher for patients treated at younger ages (Swerdlow et al, 2000; Dores et al, 2002; Hodgson et al, 2007; Schaapveld et al, 2015). However, when evaluating colon and rectum separately, the SIR of rectal cancer was not much affected by age, while colon cancer risk behaved more in line with a radiation-associated pattern, such as observed for breast (van Leeuwen et al, 2000), lung (Swerdlow et al, 2000) and stomach (van den Belt-Dusebout et al, 2009) cancer, also showing the highest SIRs among patients exposed to radiation at the very young ages.

Strengths of our study are the large size of the cohort, the detailed information on HL treatment and the long and complete follow-up for second malignancies. However, despite the large size of our cohort, the number of CRC cases was still rather low for a detailed assessment of the association of HL treatment and subsequent CRC risk. Given the large number of comparisons made in our paper we caution against over-interpretation of our findings, especially when based on small number of events. We had no information on common risk factors for CRC such as family history of CRC.

Surveillance bias is an unlikely explanation for the increased CRC risk in our study, as there have been no CRC surveillance recommendations in HL survivors. Furthermore, CRC screening in the Dutch general population was only introduced in January 2014. Since HL patients nowadays only rarely receive high-dose procarbazine in combination with infradiaphragmatic radiotherapy, we expect that CRC risk following HL will decrease. Although most patients in our cohort were treated decades ago, often with treatment regimens now considered outdated, evaluation of long-term effects of these treatments remains relevant and our findings have important implications for HL patients treated in the past. Since HL predominantly occurs at young ages, the cohort of HL survivors treated in the 1960s–1980s has only recently reached the ages at which CRC commonly occurs in the general population. Importantly, our data do not show that CRC risk levels off after longer follow-up duration. When considering more intensive CRC surveillance in HL survivors we must realise, however, that we do not know whether the pathogenesis of treatment-induced CRC in HL survivors is similar to that of CRC in the general population. As in the general population, most CRCs among HL survivors were adenocarcinomas and it appears that treatment-induced CRCs are preceded by adenomas as well (Rigter et al, 2016; Rigter et al, 2017). Currently, most screening guidelines for HL survivors do not yet include CRC screening. The Children’s Oncology Group does recommend that childhood cancer survivors exposed to > 30 Gy of abdominal radiation have a colonoscopy at least every 5 years, starting at the age of 35, or 10 years after radiation, whichever occurs last (Children’s Oncology Group, 2008). On the basis of our results, also in view of the unfavourable stage distribution and low 5-year overall survival rate, we think that CRC surveillance should be considered in HL survivors who received high-dose procarbazine and infradiaphragmatic radiotherapy, starting 10 years after first treatment but not before the age of 35 years.

ACKNOWLEDGEMENTS

We thank the Netherlands nationwide network and registry of histo- and cytopathology (PALGA) as well as the registration teams of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of the data for the Netherlands Cancer Registry.
and the scientific staff of the Netherlands Comprehensive Cancer Organisation. This work was supported by the Dutch Cancer Society (Koningin Wilhelmina Fonds, grant number NKI 2010–4720).

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**REFERENCES**

Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT (1997) Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Rad Oncol Biol Phys 37: 67–673.

Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ 82: 1–406.

Casperie M, Tiebosch ATMG, Burger G, Blauwgeers H, Van de Pol A, Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ 82: 1–406.

De Bruin ML, Burgers JA, Noordijk EM, van’t Veer MB, Noordijk EM, Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, Van de Pol A, Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ 82: 1–406.

Casparie M, Tiebosch ATMG, Burger G, Blauwgeers H, Van de Pol A, van Krieken JHJ, Meijer GA (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29(1): 19–24.

De Bruin ML, Burgers JA, Baas P, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Aleman BM, van Leeuwen FE (2009) Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 113(16): 3679–3681.

De Bruin ML, Sparidans J, van ‘t Veer MB, Noordijk E, Louwman MW, Zijlstra JM, van den Berg H, Russell N, Broeks A, Bajenais MH, Aleman BM, van Leeuwen FE (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma; lower risk after smaller radiation volumes. J Clin Oncol 27(26): 4229–4231.

Dores GM, Curtis RE, van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Roenigk HI, Joussen HI, Furrkala E, Vaalavirta I, Fossa SD, Langmark F, Travis LB, Fraumeni JF, Aleman BM, Morton LM, Gilbert ES (2014) Pancreatic cancer risk after treatment for Hodgkin lymphoma. Ann Oncol 25: 2073–2079.

Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersen M, Winklau T, Joensuu H, van’t Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 20: 3484–3494.

Favier O, Heutte N, Stamatoullas-Bastard A, Carde P, van’t Veer MB, Aleman BM, Nooridi EM, Thomas J, Ferme C, Henry-Amar M. European Organization for R, Treatment of Cancer Lymphoma Gthe. Children’s Oncology Group Long-term Follow-up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Children’s Oncology Group: Arcadia, CA, USA.

Henderson TO OK, Whitton J, Leisenring W, Neglia J, Meadows A, Crotty C, Hudon C, Armstrong GT, Robison LL, Nathan PC (2012) Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med 156(11): 757–766.

Hodgson DC, Gilbert ES, Dores GM, Schonenfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaisier M, Joensuu H, Fossa SD, Travis LB (2007) Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 25: 1489–1497.

IKNL (2012) Netherlands Comprehensive Cancer Organisation (IKNL); Dutch Cancer Figures. Available at: http://cijfersoverkanker.nl.

Land CE (1986) Carcinogenic effects of radiation on the human digestive tract and other organs. In Radiation Carcinogenesis, Upton AC, Albert RE, Burns F, Shore RE (eds) Vol. 373, pp 347–378. Elsevier: New York, NY, USA.

Lemmens V, Steenbergen LV, Jansen-Hejm M, Martijn H, Rutten H, Coebergh JW (2010) Trends in colorectal cancer in the south of the Netherlands 1975–2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 49(6): 784–796.

Morton LM, Dores GM, Curtis RE, Lynch CF, Stovall M, Hall P, Gilbert ES, Hodgson DC, Storm HH, Johensne TB, Smith SA, Weatheres RE, Andersson M, Fossa SD, Hauptmann M, Holowaty EJ, Joensuu H, Kaisier M, Kleinerman RA, Langmark F, Pukkala E, Vaalavirta I, van den Belt-Dusebout AW, Fraumeni JF, Travis LB, Aleman BM, van Leeuwen FE (2013) Stomach cancer risk after treatment for Hodgkin lymphoma. J Clin Oncol 31(27): 3369–3377.

Nakachi K, Harris CC, Tahara E (2006) Japan–US Cooperative Cancer Research Seminar on molecular epidemiological characteristics of lung and colon cancer development among atomic–bomb survivors, Bethesda, USA, February 23–24, 2006. Cancer Sci 97(11): 1279–1282.

Nakatsuka H, Shimizu Y, Yamamoto T, Sekine I, Ezaki H, Tahara E, Takahashi M, Shimoyma T, Mochinaga N, Tomita M (1992) Colorectal cancer incidence among atomic bomb survivors, 1950–80. J Radiat Res 33(4): 342–361.

Network (2012) The Cancer Genome Network. Comprehensive molecular characterization of human colon and rectal cancer. In Nature Vol. 487, pp 330–337.

Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedman JW, Mauch PM (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and factors. Blood 100(6): 1989–1996.

Naggie A, McFarlane J, Krasin MJ, Li C, Srivastava D, Robison LL, Hodgson DC, Storm HH, McDonald MM (2012) Second colorectal carcinoma after childhood cancer. J Clin Oncol 30(20): 2552–2558.

Preston DL, Ron E, Tokukoa S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K (2007) Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 168(1): 1–64.

Reulen RC, Frobisher C, Winter DL, Kelly J, Lancashire ER, Stiller CA, Pritchard-Jones K, Jenkinson HC, Hawkins MM, British Childhood Cancer Survivor Study Steering Group (2011) Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 305(22): 2311–2319.

Rigter LS, Kallenberg FG, Bastiaansen B, van OS TA, van Leeuwen FE, van Leerdam ME, Dekker E (2016) A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation? BMC Cancer 16(1): 862.

Rigter LS, Spaander MC, Moons LM, Bisseling TM, Aleman BM, de Boer JP, Lugtenburg PJ, Janus CP, Petersen EJ, Roosink JM, Raemaekers JM, van der Maazen NW, Cats A, Bleiker EM, Snellensonn P, Carvalho B, Landsorp-Vogelaar I, Jówiajek T, de Riele H, Meijer GA, van Leeuwen FE, van Leerdam ME (2017) Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer 17(1): 112.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol ADG, van der Maazen RW, Roosink J, Raemaekers JMM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PMP, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MWJ, Krul IM, Lugtenburg PJ, van Leeuwen FE (2015) Second cancer risk up to 40 years after treatment for hodgkin’s lymphoma. N Eng J Med 373(26): 2499–2511.

Schottendelf D, Winawer SJ (1982) Large intestine. In Cancer Epidemiology and Prevention, Schottendelf D, Fraumeni JF (eds), pp 703–727. W. B. Saunders: Philadelphia, PA, USA.

Schouten LJ, Straatman H, Kiemey LA, Gimbrère CH, Verbeek AL (1994) Survival after Hodgkin disease treated with radiation therapy with or without chemotherapy: a useful tool? J Clin Oncol 12: 100–106.

Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC (2008) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18(3): 498–509.

Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gillson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV (2012) Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: A National Cohort Study. J Clin Oncol 30(22): 2745–2752.

Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister TA, Radford JA, Roberts AJS, Linch DC (2011) Second cancer risk after chemotherapy for Hodgkin’s lymphoma: A Collaborative British Cohort Study. J Clin Oncol 29(31): 4096–4104.
